Nussbaum Ran — SEC Form 4 filings
SEC reporting owner CIK 1609805. 7 Form 4 filings on record with FilingPulse; latest filed 2026-06-05.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-06-03 to 2026-06-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,000,000 shares, $15,000,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 4 legs across 1 filing — 4,787,331 shares, $84,975,125 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 7.
- Largest priced transaction: sale of 2,284,612 shares @ $17.75 ($40,551,863) in Keros Therapeutics, Inc., filed 2025-10-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | Director, 10% owner | 4 | — | 4 legs · 4,787,331 sh · $84,975,125 | 3 |
| LB PHARMACEUTICALS INC (LBRX) | Director | 3 | 1 leg · 1,000,000 sh · $15,000,000 | — | 4 |
Form 4 filings — Nussbaum Ran
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-05 | 4 | LB PHARMACEUTICALS INC (LBRX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-10-17 | 4 | Keros Therapeutics, Inc. (KROS) jointly with Pontifax Management 4 G.P. (2015) Ltd., Pontifax (Israel) IV, L.P., Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P., Pontifax Late Stage Fund L.P., Pontifax Late Stage GP Ltd., Kariv Tomer | Sale (S): 2,284,612 @ $17.75 · Sale (S): 1,121,045 @ $17.75 · Sale (S): 1,226,412 @ $17.75 · Sale (S): 155,262 @ $17.75 | EDGAR |
| 2025-09-16 | 4 | LB PHARMACEUTICALS INC (LBRX) | Conversion (C): 411,681 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 10,000,000 (derivative) | EDGAR |
| 2025-09-12 | 4 | LB PHARMACEUTICALS INC (LBRX) | Grant/award (A): 22,449 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4/A | Keros Therapeutics, Inc. (KROS) | Holdings only — no transactions reported | EDGAR |
| 2025-06-06 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 5,250 @ $0 · Grant/award (A): 10,500 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Keros Therapeutics, Inc. (KROS) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1609805 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →